Skip to main navigation Skip to search Skip to main content

A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

  • Sagar Lonial
  • , Niels Van de Donk
  • , Rakesh Popat
  • , Jeffrey A. Zonder
  • , Monique Minnema
  • , Jeremy T. Larsen
  • , Tuong Vi Nguyen
  • , Min S. Chen
  • , Amine Bensmaine
  • , Teresa Peluso
  • , Pieter Sonneveld

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)E52-E53
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number10
Publication statusPublished - Oct 2019

Keywords

  • clinical trials
  • immunomodulatory drugs
  • Relapsed Refractory MM

Cite this